Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Cost of Revenue (2022 - 2025)

Historic Cost of Revenue for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $11.9 million.

  • Axsome Therapeutics' Cost of Revenue rose 4118.76% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.7 million, marking a year-over-year increase of 5136.74%. This contributed to the annual value of $33.3 million for FY2024, which is 2776.9% up from last year.
  • As of Q3 2025, Axsome Therapeutics' Cost of Revenue stood at $11.9 million, which was up 4118.76% from $13.4 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Cost of Revenue ranged from a high of $13.4 million in Q2 2025 and a low of $983000.0 during Q2 2022
  • Its 4-year average for Cost of Revenue is $7.1 million, with a median of $7.5 million in 2023.
  • In the last 5 years, Axsome Therapeutics' Cost of Revenue surged by 36785.35% in 2023 and then crashed by 1666.23% in 2024.
  • Over the past 4 years, Axsome Therapeutics' Cost of Revenue (Quarter) stood at $2.3 million in 2022, then soared by 222.04% to $7.4 million in 2023, then skyrocketed by 42.5% to $10.5 million in 2024, then rose by 13.3% to $11.9 million in 2025.
  • Its Cost of Revenue stands at $11.9 million for Q3 2025, versus $13.4 million for Q2 2025 and $9.8 million for Q1 2025.